Edition:
United Kingdom

Knight Therapeutics Inc (GUD.TO)

GUD.TO on Toronto Stock Exchange

8.20CAD
20 Sep 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$8.20
Open
$8.17
Day's High
$8.25
Day's Low
$8.12
Volume
59,681
Avg. Vol
102,331
52-wk High
$9.11
52-wk Low
$7.38

Latest Key Developments (Source: Significant Developments)

Knight Therapeutics Says ‍Will Have Exclusive Rights To Market And Sell Tenapanor In Canada​
Monday, 19 Mar 2018 

March 19 (Reuters) - Ardelyx Inc ::KNIGHT THERAPEUTICS - ‍LICENSE AGREEMENT WITH ARDELYX THAT PROVIDES KNIGHT WITH EXCLUSIVE RIGHTS TO COMMERCIALIZE TENAPANOR IN CANADA​.KNIGHT THERAPEUTICS - ‍WILL PAY UP TO C$25 MILLION IN TOTAL PAYMENTS INCLUDING AN UPFRONT PAYMENT AND DEVELOPMENT AND SALES MILESTONES.KNIGHT THERAPEUTICS INC - ‍KNIGHT WILL HAVE EXCLUSIVE RIGHTS TO MARKET AND SELL TENAPANOR IN CANADA​.  Full Article

Knight Reports Qtrly Basic Earnings Per Share $0.05
Thursday, 15 Mar 2018 

March 15 (Reuters) - Knight Therapeutics Inc ::KNIGHT REPORTS 2017 FOURTH QUARTER AND YEAR END RESULTS.QTRLY BASIC EARNINGS PER SHARE $0.05.QTRLY REVENUES $2.5 MILLION VERSUS $1.8 MILLION.Q4 EARNINGS PER SHARE VIEW C$0.04, REVENUE VIEW C$2.1 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Knight Therapeutics Says New Drug Submission For Netildex Accepted For Review By Health Canada​
Thursday, 15 Feb 2018 

Feb 15 (Reuters) - Knight Therapeutics Inc ::KNIGHT THERAPEUTICS AND SIFI S.P.A. ANNOUNCE FILING OF NEW DRUG SUBMISSION FOR NETILDEX IN CANADA.KNIGHT THERAPEUTICS INC - ‍KNIGHT'S NEW DRUG SUBMISSION FOR NETILDEX HAS BEEN ACCEPTED FOR REVIEW BY HEALTH CANADA​.  Full Article

KNIGHT THERAPEUTICS REPORTS Q3 EARNINGS PER SHARE $0.03
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Knight Therapeutics Inc :KNIGHT REPORTS THIRD QUARTER 2017 RESULTS.QTRLY ‍REVENUE $1.9 MILLION, A DECREASE OF 2 PERCENT​.QTRLY EARNINGS PER SHARE $0.03‍​.‍ALL CURRENCIES ARE CANADIAN​.  Full Article

Knight Therapeutics reports qtrly earnings per share $0.03‍​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Knight Therapeutics Inc ::Knight reports third quarter 2017 results.Qtrly earnings per share $0.03.Q3 earnings per share view C$0.03 -- Thomson Reuters I/B/E/S‍​.Qtrly ‍revenues were $1.9 million, a decrease of 2 percent versus same period in prior year​.All currencies are Canadian‍​.  Full Article

Knight Therapeutics announces increase in ownership of Crescita Therapeutics
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Knight Therapeutics Inc :Knight Therapeutics - ‍pursuant to early warning requirements of national instrument 62-103, co announced increase in ownership of Crescita Therapeutics.Knight Therapeutics Inc - ‍now owns aggregate of 2.08 million common shares of crescita representing about 14.9 pct of outstanding common shares of Crescita​.  Full Article

Knight Therapeutics amended its secured loan agreement with Crescita Therapeutics
Monday, 14 Aug 2017 

Aug 14 (Reuters) - Crescita Therapeutics Inc :Knight Therapeutics Inc - Amended its secured loan agreement with Crescita Therapeutics Inc.Knight Therapeutics - To receive early repayment of $2.5 million of loan, agreed to release letter of credit for general security interest over all of Crescita's assets.  Full Article

Crescita Therapeutics announces amended loan agreement with Knight Therapeutics
Monday, 14 Aug 2017 

Aug 14 (Reuters) - Crescita Therapeutics Inc :Crescita Therapeutics announces amended loan agreement with Knight Therapeutics.Crescita Therapeutics Inc - ‍announced it has entered into an amended loan agreement with Knight Therapeutics Inc​.Crescita Therapeutics Inc - ‍under terms of amended loan agreement, Crescita will immediately repay $2.5 million of loan​.Crescita Therapeutics Inc - Knight has agreed to release letter of credit in exchange for a general security interest over all of Crescita's assets​.Crescita Therapeutics - has access to additional $6.0 million of cash that was previously restricted under terms of letter of credit - to fund operations​.Crescita Therapeutics - ‍loan continues to bear interest at 9% per annum and matures on January 22, 2022​.Entered into an amended loan agreement with knight therapeutics inc.Crescita agreed to make additional repayments such that principal amount of loan is reduced to $2.5 million by December 31, 2018​.  Full Article

Knight Therapeutics qtrly earnings per share $‍0.003​
Thursday, 10 Aug 2017 

Aug 10 (Reuters) - Knight Therapeutics Inc ::Knight reports second quarter 2017 results.Qtrly earnings per share $‍0.003​.  Full Article

Knight Therapeutics reports second quarter 2017 results
Thursday, 10 Aug 2017 

Aug 10 (Reuters) - Knight Therapeutics Inc :Knight reports second quarter 2017 results.Qtrly ‍shr $0.003​.All figures in C$.  Full Article